Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282

Molecular Cancer Therapeutics

Volumn 10, Issue 8, 2011, Pages 1490-1499

  Sooryakumar, Dhriti ^a   Dexheimer, Thomas S ^a   Teicher, Beverly A ^b   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; DRUG METABOLITE; GENZ 644282; GENZ 649974; GENZ 649975; GENZ 649978; GLYCOPROTEIN P; HISTONE H2AX GAMMA; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEAR PROTEIN; TOPOTECAN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL LINE; CELL POPULATION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DNA CLEAVAGE; DNA CROSS LINKING; DNA STRAND BREAKAGE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CAMPTOTHECIN; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; HCT116 CELLS; HISTONES; HUMANS; NAPHTHYRIDINES; NEOPLASMS; TOPOISOMERASE I INHIBITORS;

EID: 80051601579     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-1043     Document Type: Article

References (42)

1. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802. (Pubitemid 44450467)
2. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001;70:369-413. (Pubitemid 32662215)
3. Wang JC. A journey in the world of DNA rings and beyond. Annu Rev Biochem 2009;78:31-54.
4. Teicher BA. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol 2008;75:1262-71. (Pubitemid 351305209)
5. Thomas CJ, Rahier NJ, Hecht SM. Camptothecin: current perspectives. Bioorg Med Chem 2004;12:1585-604. (Pubitemid 38344159)
6. Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev 2009;109:2894-902.
7. Furuta T, Takemura H, Liao ZY, Aune GJ, Redon C, Sedelnikova OA, et al. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA-double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 2003;278:20303-12. (Pubitemid 36799229)
8. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. GammaH2AX and cancer. Nat Rev Cancer 2008;8:957-67.
9. Nakamura AJ, Rao VA, Pommier Y, Bonner WM. The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks. Cell Cycle 2010;9:389-97.
10. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB Jr, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A 2002;99:15387-92. (Pubitemid 35403944)
11. Ioanoviciu A, Antony S, Pommier Y, Staker BL, Stewart L, Cushman M. Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. J Med Chem 2005;48:4803-14. (Pubitemid 41033123)
12. Pommier Y, Cherfils J. Interfacial protein inhibition: a nature's paradigm for drug discovery. Trends Pharmacol Sci 2005;28:136-45.
13. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999;59:5938-46. (Pubitemid 30004955)
14. Takagi K, Dexheimer TS, Redon C, Sordet O, Agama K, Lavielle G, et al. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters. Mol Cancer Ther 2007;6:3229-38.
15. Long BH, Rose WC, Vyas DM, Matson JA, Forenza S. Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles. Curr Med Chem Anticancer Agents 2002;2:255-66. (Pubitemid 34649875)
16. Pommier Y, Cushman M. The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. Mol Cancer Ther 2009;8:1008-14.
17. Antony S, Agama KK, Miao ZH, Takagi K, Wright MH, Robles AI, et al. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res 2007;67:10397-405. (Pubitemid 350070815)
18. Li TK, Houghton PJ, Desai SD, Daroui P, Liu AA, Hars ES, et al. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res 2003;63:8400-7. (Pubitemid 37549495)
19. Kurtzberg LS, Roth S, Krumbholz R, Crawford J, Bormann C, Dunham S, et al. Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment. Clin Cancer Res 2011;17:2777-87.
20. Nagarajan M, Morrell A, Ioanoviciu A, Antony S, Kohlhagen G, Agama K, et al. Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles. J Med Chem 2006;49:6283-9. (Pubitemid 44595205)
21. Lorenzi PL, Reinhold WC, Varma S, Hutchinson AA, Pommier Y, Chanock SJ, et al. DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther 2009;8:713-24.
22. Miao ZH, Player A, Shankavaram U, Wang YH, Zimonjic DB, Lorenzi PL, et al. Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res 2007;67:8752-61. (Pubitemid 47437451)
23. Chatterjee D, Wyche JH, Pantazis P. Induction of apoptosis in malignant and camptothecin-resistant human cells. Ann N Y Acad Sci 1996;803:143-56. (Pubitemid 27057981)
24. Urasaki Y, Laco G, Pourquier P, Takebayashi Y, Kohlhagen G, Gioffre C, et al. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res 2001;61:1964-9. (Pubitemid 32692014)
25. Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell resistant to camptothecin. Cancer Res 1995;55:1339-46.
26. Fujimori A, Hoki Y, Popescu NC, Pommier Y. Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells. Oncol Res 1996;8:295-301. (Pubitemid 26404136)
27. Dexheimer TS, Pommier Y. DNA cleavage assay for the identification of topoisomerase I inhibitors. Nat Protoc 2008;3:1736-50.
28. Shaw JL, Blanco J, Mueller GC. A simple procedure for isolation of DNA, RNA and protein fractions from cultured animal cells. Anal Biochem 1975;65:125-31.
29. Subramanian D, Kraut E, Staubus A, Young DC, Muller MT. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res 1995;55:2097-103.
30. Covey JM, Jaxel C, Kohn KW, Pommier Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 1989;49:5016-22. (Pubitemid 19239335)
31. Kohn KW. DNA filter elution: a window on DNA damage in mammalian cells. Bioessays 1996;18:505-13. (Pubitemid 126599979)
32. Pommier Y, Covey JM, Kerrigan D, Markovits J, Pham R. DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators. Nucleic Acids Res 1987;15:6713-31. (Pubitemid 17134366)
33. Marchand C, Antony S, Kohn KW, Cushman M, Ioanoviciu A, Staker BL, et al. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of topoisomerase I-DNA covalent complexes. Mol Cancer Ther 2006;5:287-95.
34. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994;86:836-42. (Pubitemid 24164661)
35. Ross WE, Glaubiger DL, Kohn KW. Protein-associated DNA breaks in cells treated with adriamycin or ellipticine. Biochim Biophys Acta 1978;519:23-30. (Pubitemid 8371696)
36. Seiler JA, Conti C, Syed A, Aladjem MI, Pommier Y. The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol Cell Biol 2007;27:5806-18. (Pubitemid 47257835)
37. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58. (Pubitemid 37328807)
38. Staker BL, Feese MD, Cushman M, Pommier Y, Zembower D, Stewart L, et al. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem 2005;48:2336-45. (Pubitemid 40516428)
39. Tewey KM, Chen GL, Nelson EM, Liu LF. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984;259:9182-7. (Pubitemid 14098903)
40. Pommier Y, Schwartz RE, Kohn KW, Zwelling LA. Formation and rejoining of deoxyribonucleic acid double-strand breaks induced in isolated cell nuclei by antineoplastic intercalating agents. Biochemistry 1984;23:3194-201. (Pubitemid 14056884)
41. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem 2000;275:9390-5. (Pubitemid 30185164)
42. Solier S, Pommier Y. The apoptotic ring: a novel entity with phosphorylated histones H2AX and H2B and activated DNA damage response kinases. Cell Cycle 2009;8:1853-9.